Drugmaker Tactic to Block Generics May Violate Law, FTC SaysBy
FTC files amicus brief in Mylan appeal over antibiotic Doryx
Some drugmakers tweak products to extend patent protection
Pharmaceutical companies that make minor tweaks to brand-name drugs in order to blunt competition from cheaper generic treatments may be violating antitrust laws, the U.S. Federal Trade Commission said.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.